# A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients

> **NCT01661088** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** FOLFIRINOX
- **RADIATION:** Intensity-modulated radiotherapy (IMRT)
- **PROCEDURE:** Surgical Exploration

## Key facts

- **NCT ID:** NCT01661088
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2017-08-10
- **Final completion:** 2019-08-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01661088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01661088, "A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01661088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*